Literature DB >> 8601968

Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations.

M Seghaye1, J Duchateau, J Bruniaux, S Demontoux, C Bosson, A Serraf, G Lecronier, E Mokhfi, C Planche.   

Abstract

To evaluate cytokine balance related to cardiopulmonary bypass, we prospectively investigated 11 infants undergoing cardiac operations for congenital heart disease. Proinflammatory cytokines (tumor necrosis factor-alpha and interleukin-8) and the antiinflammatory cytokine interleukin-10 were measured at multiple time points before, during, and after bypass. Tumor necrosis factor-alpha and interleukin-8 values were within normal range before the operation. These values increased significantly during bypass, reaching their peaks after protamine administration (tumor necrosis factor-alpha, 133.6 +/- 124.9 pg/ml; mean +/- standard deviation; p<0.005) and 2 hours after termination of the procedure (interleukin-8, 92.1 +/- 44.1 pg/ml; p < 0.01). Tumor necrosis factor-alpha and interleukin-8 equaled normal prebypass values from the first postoperative day on. Interleukin-10 levels were within normal range before the operation and were already significantly increased 10 minutes after initiation of bypass (interleukin 10, 39.4 +/- 34.3 pg/ml; p<0.05). These levels remained elevated throughout the procedure but returned to normal after protamine administration. A second significant release of interleukin-10 occurred from the early postoperative period on, reaching its peak 24 hours after termination of cardiopulmonary bypass (interleukin-10, 351.6 +/- 304.0 pg/ml; p < 0.01). Interleukin-10 values were normal on the second postoperative day in all patients. Interleukin-10 kinetics showed an inverse pattern compared with tumor necrosis factor-alpha and interleukin-8. This difference suggests an interplay between proinflammatory and antiinflammatory cytokines released during and after cardiopulmonary bypass. Interleukin-10 levels measured 4 and 24 hours after bypass strongly correlated with the degree of hypothermia during bypass (Spearman's correlation coefficient, -0.77 [p < 0.01] and -0.89 [p < 0.0005], respectively); these levels did not correlate with duration of bypass and aortic crossclamping, however. This result suggests that besides immunologically mediated production of interleukin-10, hypothermia itself could modulate interleukin-10 production. In conclusion, this study demonstrates interleukin-10 production, in addition to interleukin-8 and tumor necrosis factor-alpha synthesis, in response to cardiopulmonary bypass in infants. Interleukin-10 could play a protective role by down-regulating proinflammatory cytokine release during and after cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8601968     DOI: 10.1016/s0022-5223(96)70306-9

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  15 in total

1.  Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin as a circuit coating material.

Authors:  Hitoshi Izuha; Momoe Hattori; Tsuguo Igari; Daiki Wakamatsu; Mdtoshiki Watanabe; Hitoshi Yokoyama
Journal:  J Artif Organs       Date:  2005       Impact factor: 1.731

2.  Effects of preinjury administration of corticosteroids on pseudointimal hyperplasia and cytokine response in a rat model of balloon aortic injury.

Authors:  Kazuhito Nagasaki; Kenji Matsumoto; Munehisa Kaneda; Tsunehiro Shintani; Shintaro Shibutani; Takaya Murayama; Go Wakabayashi; Motohide Shimazu; Makio Mukai; Masaki Kitajima
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

3.  Interindividual variations in cytokine levels following cardiopulmonary bypass.

Authors:  M Misoph; J Babin-Ebell
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

4.  Randomized trial of the Terumo Capiox FX05 oxygenator with integral arterial filter versus Terumo Capiox Baby RX05 and Terumo Capiox AF02 arterial filter in infants undergoing cardiopulmonary bypass.

Authors:  Mark M Nuszkowski; Nina Deutsch; Richard A Jonas; David Zurakowski; Erin Montague; David W Holt
Journal:  J Extra Corpor Technol       Date:  2011-12

5.  Multiplex serum cytokine immunoassay using nanoplasmonic biosensor microarrays.

Authors:  Pengyu Chen; Meng Ting Chung; Walker McHugh; Robert Nidetz; Yuwei Li; Jianping Fu; Timothy T Cornell; Thomas P Shanley; Katsuo Kurabayashi
Journal:  ACS Nano       Date:  2015-03-23       Impact factor: 15.881

6.  Different proinflammatory cytokine serum pattern in neonate patients undergoing open heart surgery. Relevance of IL-8.

Authors:  A J Alcaraz; L Manzano; L Sancho; M D Vigil; F Esquivel; E Maroto; E Reyes; M Alvarez-Mon
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

7.  Evaluation of the effects of ozone therapy in the treatment of intra-abdominal infection in rats.

Authors:  Yglesio Moyses de Souza; Belchor Fontes; Joilson O Martins; Paulina Sannomiya; Glacus S Brito; Riad N Younes; Samir Rasslan
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

8.  Serum TNF-α levels in children with congenital heart disease undergoing cardiopulmonary bypass: A cohort study in China and a meta-analysis of the published literature.

Authors:  Shu-Tian Song; Chuan-Ming Bai; Ji-Wu Zhou
Journal:  J Clin Lab Anal       Date:  2016-12-13       Impact factor: 2.352

9.  Antibody-modified conduits for highly selective cytokine elimination from blood.

Authors:  J Brian McAlvin; Ryan G Wylie; Krithika Ramchander; Minh T Nguyen; Charles K Lok; Morgan Moroi; Andre Shomorony; Nikolay V Vasilyev; Patrick Armstrong; Jason Yang; Alexander M Lieber; Obiajulu S Okonkwo; Rohit Karnik; Daniel S Kohane
Journal:  JCI Insight       Date:  2018-07-12

10.  STAT3 regulates monocyte TNF-alpha production in systemic inflammation caused by cardiac surgery with cardiopulmonary bypass.

Authors:  Petrus R de Jong; Alvin W L Schadenberg; Theo van den Broek; Jeffrey M Beekman; Femke van Wijk; Paul J Coffer; Berent J Prakken; Nicolaas J G Jansen
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.